NEW YORK — BioAffinity Technologies said Wednesday that its CyPath Lung test for early-stage lung cancer detection has been added to the US Federal Supply Schedule.
The US Federal Supply Schedule is a procurement system used by the Veterans Health Administration and Military Health System to access commercial products and services.
CyPath Lung is a laboratory-developed assay that uses self-collected sputum samples treated with a fluorescent compound that preferentially binds to cancer cells and cancer-related cells, San Antonio-based BioAffinity said. Cells are further stained with fluorescently labeled antibodies that identify hematopoietic and epithelial cells.
The sample is then run through a flow cytometer and the resulting data is analyzed to detect lung cancer in patients at high risk for the disease who have small lung nodules less than 20 millimeters.
CyPath Lung is marketed by BioAffinity subsidiary Precision Pathology Laboratory Services.